Søren Møller
Director/Board Member bij GALECTO, INC.
Oorsprong van het eerstegraads netwerk van Søren Møller
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Technical University of Denmark
54
| College/University | Other Consumer Services | 54 |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) MiscellaneousMiscellaneous Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.
31
| Subsidiary | Miscellaneous | 31 |
Novozymes A/S
 Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark.
23
| Extinct | Chemicals: Specialty | 23 |
| Public Company | Pharmaceuticals: Major | 19 | |
Novo Seeds
 Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark.
16
| Operating Division | Investment Managers | 16 |
NorthSea Therapeutics BV
 NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands.
12
| Holding Company | Biotechnology | 12 |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark.
11
| Subsidiary | Pharmaceuticals: Major | 11 |
Reapplix A/S
 Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark.
11
| Holding Company | Medical Distributors | 11 |
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark.
10
| Private Company | Miscellaneous Commercial Services | 10 |
Forendo Pharma Oy
 Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland.
9
| Subsidiary | Pharmaceuticals: Major | 9 |
Biosyntia ApS
 Biosyntia ApS BiotechnologyHealth Technology Biosyntia ApS provides services in synthetic biology and metabolic engineering fields. It offers biocatalysts for fermentation of fine chemicals. The company was founded by Andreas Hougaard Laustsen, Morten Otto Alexander Sommer, and Hans Jasper Genee in 2012 and is headquartered in Copenhagen, Denmark.
7
| Holding Company | Biotechnology | 7 |
Advanced MR Analytics AB
 Advanced MR Analytics AB Medical SpecialtiesHealth Technology Advanced MR Analytics AB offers solutions for body composition analysis. It transforms subjective magnetic resonance images into fat and muscle measurements. The firm provides technical research such as data acquisition and reconstruction; registration and fusion; machine learning and signal representation; modelling and simulation; simulation, classification, and quantification; visualization and image enhancement; and user interfaces and interaction. The company was founded by David Magnus Borga and Olof Erik Gunnar Dahlqvist Leinhard in 2010 and is headquartered in Link?ping, Sweden.
6
| Holding Company | Medical Specialties | 6 |
Affinicon ApS
 Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Ejendomsselskabet Hvidovre Torv AS
 Ejendomsselskabet Hvidovre Torv AS Real Estate DevelopmentFinance Part of Ejendomsselskabet Hvidovre Torv Holding AS, Ejendomsselskabet Hvidovre Torv AS engages in rental of commercial real estate properties. The private company is based in Aarhus, Denmark.
4
| Subsidiary | Real Estate Development | 4 |
| Extinct | Miscellaneous Commercial Services | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Søren Møller via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Director/Board Member Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal General Counsel | |
| NOVARTIS AG | Pharmaceuticals: Major | Investor Relations Contact Director of Finance/CFO | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Graduate Degree | |
| Stanford University | College/University | Corporate Officer/Principal Doctorate Degree | |
| CARLSBERG A/S | Beverages: Alcoholic | Director/Board Member Corporate Officer/Principal Chief Executive Officer | |
| ROCKWOOL A/S | Construction Materials | Director/Board Member Chairman | |
Novo Nordisk Fonden
 Novo Nordisk Fonden Investment Trusts/Mutual FundsMiscellaneous Novo Nordisk Fonden provides basis for the commercial and research activities conducted by the companies. It also supports scientific and humanitarian purposes activities. It awards grants for research within biomedicine, biotechnology, general practice and family medicine, nursing, and art history at public research institutions. It bridges gap between the discoveries made by researchers in biomedicine and biotechnology and their commercial application. The company was founded by August Krogh, Marie Krogh, Harald Pedersen, Hans Christian Hagedorn, August Kongsted and Thorvald Pedersen in 1922 and is headquartered in Hellerup, Denmark. | Investment Trusts/Mutual Funds | Chairman Chief Executive Officer Director/Board Member | |
| SCANDINAVIAN INVESTMENT GROUP A/S | Real Estate Investment Trusts | Director/Board Member Director/Board Member | |
| University of Oxford | College/University | Undergraduate Degree Corporate Officer/Principal Undergraduate Degree | |
Carlsberg Breweries A/S
 Carlsberg Breweries A/S Beverages: AlcoholicConsumer Non-Durables Carlsberg Breweries A/S engages in the production and marketing of beer and soft drinks. The firm's brands include Afsana, Backyard Brew, CELIA, Dahls, and Eriksberg. It operates through the following geographical segments: Western Europe; Asia; Eastern Europe; and Central and Eastern Europe. The company was founded by Jacob Christian Jacobsen in 1847 and is headquartered in Copenhagen, Denmark. | Beverages: Alcoholic | Chairman Chief Executive Officer | |
Sofinnova Partners SAS
 Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Investment Managers | Private Equity Investor Private Equity Investor | |
| University of Cambridge | College/University | Graduate Degree Doctorate Degree Masters Business Admin | |
Wellington Partners GmbH
 Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Investment Managers | Private Equity Investor Private Equity Investor | |
Proteopharma AS
 Proteopharma AS Pharmaceuticals: MajorHealth Technology Part of 5AM Venture Management LLC, Proteopharma AS is a Danish pharmaceutical company that manufactures pharmaceuticals. The private company is based in Aarhus, Denmark. The company was founded by Niels Jonas Heilskov Graversen and Søren Kragh Moestrup. Proteopharma was acquired by Borean Pharma ApS on February 16, 2004. | Pharmaceuticals: Major | Founder Founder | |
| Copenhagen Business School | College/University | Undergraduate Degree Graduate Degree Masters Business Admin Graduate Degree Graduate Degree | |
| University of Aarhus | College/University | Director/Board Member Doctorate Degree Corporate Officer/Principal Graduate Degree Graduate Degree Undergraduate Degree | |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director of Finance/CFO | |
Hormos Medical Oy
 Hormos Medical Oy Pharmaceuticals: MajorHealth Technology Hormos Medical Oy discovers and develops novel hormonal therapies. It provides research and development of products to treat endocrine disorders associated with aging. The company was founded by Risto Arvo Sakari Lammintausta and Lauri Kangas in 1997 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Chief Executive Officer Founder | |
| University of Copenhagen | College/University | Graduate Degree Director/Board Member Doctorate Degree Doctorate Degree Graduate Degree Graduate Degree Graduate Degree Doctorate Degree Graduate Degree Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal Doctorate Degree Undergraduate Degree Doctorate Degree Graduate Degree | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Founder Private Equity Investor Private Equity Investor | |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal General Counsel Director/Board Member | |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Investment Managers | Private Equity Investor Private Equity Investor | |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Private Equity Investor Private Equity Investor | |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor Director of Investments Chief Investment Officer Private Equity Investor Corporate Officer/Principal | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member Corporate Officer/Principal Director/Board Member | |
Cell Medica Switzerland AG
 Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Novo Principal Investments
 Novo Principal Investments Investment ManagersFinance Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | President Chief Executive Officer Private Equity Investor Private Equity Investor | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member Director/Board Member | |
Minervax ApS
 Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
| KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Chairman Director/Board Member Director/Board Member | |
Pcovery ApS
 Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
iSD Immunotech ApS
 iSD Immunotech ApS BiotechnologyHealth Technology iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Avilex Pharma ApS
 Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| RUBIUS THERAPEUTICS | Biotechnology | Director/Board Member Director/Board Member | |
IO Biotech ApS
 IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Chief Executive Officer Chairman | |
Merck Ventures BV
 Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Analyst Private Equity Investor Private Equity Analyst | |
Novo Holdings A/S (Investment Company)
 Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Financial Conglomerates | Chief Investment Officer Chairman Chief Executive Officer | |
| IO BIOTECH, INC. | Biotechnology | Director/Board Member Director/Board Member Founder | |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Chairman Director/Board Member Chief Executive Officer |
Statistieken
Internationaal
| Denemarken | 27 |
| Verenigde Staten | 9 |
| Nederland | 4 |
| Zwitserland | 3 |
| Verenigd Koninkrijk | 3 |
Sectoraal
| Health Technology | 25 |
| Finance | 12 |
| Consumer Services | 8 |
| Consumer Non-Durables | 3 |
| Commercial Services | 2 |
Operationeel
| Director/Board Member | 825 |
| Corporate Officer/Principal | 210 |
| Chairman | 143 |
| Independent Dir/Board Member | 136 |
| Chief Executive Officer | 106 |
Sterkste connecties
- Beurs
- Insiders
- Søren Møller
- Bedrijfsconnecties
